Jazz Pharmaceuticals (JAZZ) Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Is JAZZ or AXSM more profitable?

Jazz Pharmaceuticals has a net margin of 11.86% compared to Axsome Therapeutics' net margin of -64.39%. Jazz Pharmaceuticals' return on equity of 26.62% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	11.86%	26.62%	9.14%
Axsome Therapeutics	-64.39%	-272.80%	-36.69%

Which has higher valuation and earnings, JAZZ or AXSM?

Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.06B	1.60	$560.12M	$7.50	14.35
Axsome Therapeutics	$385.69M	13.72	-$287.22M	-$5.77	-18.63

Which has more volatility and risk, JAZZ or AXSM?

Jazz Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Do analysts recommend JAZZ or AXSM?

Jazz Pharmaceuticals currently has a consensus target price of $184.00, suggesting a potential upside of 71.00%. Axsome Therapeutics has a consensus target price of $172.33, suggesting a potential upside of 60.31%. Given Jazz Pharmaceuticals' higher probable upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	3.06

Do institutionals & insiders have more ownership in JAZZ or AXSM?

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 22.4% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media favor JAZZ or AXSM?

In the previous week, Axsome Therapeutics had 8 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 17 mentions for Axsome Therapeutics and 9 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.78 beat Axsome Therapeutics' score of -0.04 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Jazz Pharmaceuticals beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.